Mirum SVP Howe sells 968 shares after RSU vest

Mirum Pharmaceuticals SVP and Global Controller Jolanda Howe reported routine equity compensation activity.

Rhea-AI Filing Summary

Mirum Pharmaceuticals SVP and Global Controller Jolanda Howe reported routine equity compensation activity. On January 31, 2026, 1,771 restricted stock units vested and were converted into an equal number of common shares at an exercise price of $0.

On February 2, 2026, Howe sold 968 shares of common stock at a price of $103.3035 per share to cover tax withholding obligations related to the vesting. After these transactions, Howe directly owned 4,503 shares of Mirum Pharmaceuticals common stock.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Howe Jolanda

Role SVP, GLOBAL CONTROLLER

Sold 968 shs ($100K)

Approx. gross sale proceeds $100K

Approx. exercise cost $0.00

Type	Security	Shares	Price	Value
Sale	Common Stock	968	$103.3035	$100K
Exercise	Restricted Stock Units	1,771	$0.00	$0.00
Exercise	Common Stock	1,771	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 0 contracts (Direct); Common Stock — 4,503 shares (Direct)

Footnotes (3)

1. F1. Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer).
2. F2. Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.
3. F3. The restricted stock units vest in a series of three successive equal annual installments beginning January 31, 2024. 1,772 shares vested on January 31, 2024 ; 1,772 shares vested January 31, 2025 and the remaining 1,771 shares will vest on January 31, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Mirum (MIRM) disclose for Jolanda Howe?

Mirum disclosed that SVP and Global Controller Jolanda Howe had 1,771 restricted stock units vest into common shares, then sold 968 shares. The sale was to cover tax withholding obligations, and she held 4,503 common shares directly after these transactions.

How many Mirum (MIRM) shares did Jolanda Howe sell and at what price?

Jolanda Howe sold 968 shares of Mirum Pharmaceuticals common stock at $103.3035 per share. The sale occurred on February 2, 2026 and was specifically noted as covering tax withholding obligations from the vesting of restricted stock units.

What equity award vested for Mirum (MIRM) executive Jolanda Howe?

On January 31, 2026, 1,771 restricted stock units held by Jolanda Howe vested and converted into the same number of Mirum common shares at a $0 exercise price. These units were part of a three-year vesting schedule beginning January 31, 2024.

How many Mirum (MIRM) shares does Jolanda Howe own after the reported Form 4?

Following the vesting and subsequent sale to cover taxes, Jolanda Howe directly owned 4,503 shares of Mirum Pharmaceuticals common stock. This figure reflects her beneficial ownership after the 1,771-share vesting and the 968-share sale on February 2, 2026.

Why did Jolanda Howe’s Mirum (MIRM) Form 4 show both RSUs and common stock?

The Form 4 shows derivative restricted stock units that vested and converted into common shares, and the resulting common stock holdings. RSUs represented a contingent right to receive shares, which became 1,771 common shares that were then partly sold to cover tax withholding.

What is the vesting schedule of Jolanda Howe’s Mirum (MIRM) restricted stock units?

The restricted stock units vest in three equal annual installments starting January 31, 2024. 1,772 shares vested on January 31, 2024, another 1,772 on January 31, 2025, and the final 1,771 units vested on January 31, 2026, delivering common shares each year.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/03/2026 - 09:45 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Howe Jolanda

(Last) (First) (Middle)

C/O MIRUM PHARMACEUTICALS, INC.

989 E HILLSDALE BLVD., SUITE 300

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, GLOBAL CONTROLLER

3. Date of Earliest Transaction (Month/Day/Year)
01/31/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/31/2026		M		1,771	A	(1)	5,471	D
Common Stock	02/02/2026		S(2)		968	D	$103.3035	4,503	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/31/2026		M			1,771	(3)	(3)	Common Stock	1,771	$0	0	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer).

2. Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.

3. The restricted stock units vest in a series of three successive equal annual installments beginning January 31, 2024. 1,772 shares vested on January 31, 2024 ; 1,772 shares vested January 31, 2025 and the remaining 1,771 shares will vest on January 31, 2026.

	/s/ Judit Ryvkin, Attorney-in-Fact	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.